A single IV dose of the factor XI monoclonal antibody abelacimab appeared superior to daily enoxaparin for preventing venous thromboembolism after total knee arthroplasty, according to randomized study results. The results — presented at International Society on Thrombosis and Hemostasis Congress and published in The New England Journal of Medicine — showed abelacimab (Anthos Therapeutics) reduced blood […]

July 19 (UPI) — The drug abelacimab prevents blood clots in patients undergoing knee replacement surgery, a study published by the New England Journal of Medicine found. Abelacimab, developed by Cambridge, Mass.-based Anthos Therapeutics, reduced the risk for blood clots in people who had the procedure by about 80% compared with the blood-thinner enoxaparin, the data showed.

Dr. Ryan Mathis is the Vice President of Commercial Strategy at PolarityTE, focusing on bringing regenerative medicine into clinical practice, particularly for treating diabetic foot ulcers and other forms of complex wounds. Ryan says, “So, we’re trying to solve this problem by developing SkinTE, which is revolutionizing the science for these hard-to-close wounds. The product itself […]